76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis

G. Justeau; M. Pérol; C. Audigier Valette; D. Debieuvre; X. Quantin; H. Lena; P. Macouillard; L. Bosquet; M.J. Schoemaker; M. Mella; B. Correia; C. Rault; M.J. Daumont; J. Penrod; C. Chouaid

doi:10.1016/j.iotech.2023.100548

Retour

76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis

Article de revue

Avec comité de lecture

76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis

G. Justeau, M. Pérol, C. Audigier Valette, D. Debieuvre, X. Quantin, H. Lena, P. Macouillard, L. Bosquet, M.J. Schoemaker, M. Mella, …

Immuno-oncology technology, Vol.20, p.100548

12/2023

DOI: https://doi.org/10.1016/j.iotech.2023.100548

Indicateurs

1 Consultations de la notice

Détails

Titre: 76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis
Créateurs - sans rôle: G. Justeau - Pulmonology Dept., CHU Angers, Angers, France
M. Pérol - Medical Oncology Dept., Centre Léon Bérard, Lyon, France
C. Audigier Valette - Pneumo-Oncology, Hopital Sainte Musse, Toulon, France
D. Debieuvre - Pneumology, GHRMSA, Mulhouse, France
X. Quantin - Medical Oncology, ICM - Institut du Cancer de Montpellier, Montpellier, France
H. Lena - Pneumology, Hop Pontchaillou, Rennes, France
P. Macouillard - Health Data and Partnerships Department, Unicancer, Paris, France
L. Bosquet - Health Data and Partnerships Department, Unicancer, Paris, France
M.J. Schoemaker - Global Database Studies, IQVIA Nederland, Amsterdam, Netherlands
M. Mella - Global Database Studies, IQVIA Italy, Cassina de' Pecchi, Italy
B. Correia - Global Database Studies, IQVIA Portugal, Porto Salvo, Portugal
C. Rault - Epidemiology, Data Gnosis, Rennes, France
M.J. Daumont - Worldwide HEOR, Bristol Myers Squibb Belgium SA, Brussels, Belgium
J. Penrod - Worldwide HEOR, Bristol Myers Squibb, Princeton, NJ, USA
C. Chouaid - Worldwide HEOR, CH Intercommunal de Créteil, Créteil, France
Détails de publication: Immuno-oncology technology, Vol.20, p.100548
Éditeur: Elsevier Ltd
Identifiants: 99141264409311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article